Introduction
============

Meibomian gland dysfunction (MGD) may well be the leading cause of dry eye disease throughout the world,[@b1-opth-8-831] and is the most common reason for ophthalmology consultation in daily practice. Increased meibum viscosity and hyperkeratinization of the ductal epithelium are the main mechanisms of obstructive MGD.[@b2-opth-8-831] Also, the tear film lipid layer is the major barrier to evaporation from the ocular surface. The tear film contains a complex mixture of proteins, enzymes, lipids, mucins, and salts that allow the tear film to perform its functions.[@b3-opth-8-831] A decrease in its thickness or functional integrity may cause evaporative dry eye. Although the etiology of MGD may differ from that of aqueous-deficient dry eye disease (due to insufficient lacrimal gland production), the two conditions share many clinical features, including symptoms of ocular surface irritation and visual acuity fluctuation, altered tear film stability, and potential compromise of the ocular surface.

Population-based and clinical cohort studies have shown that the prevalence of MGD varies widely from 3.5% to almost 70%,[@b4-opth-8-831],[@b5-opth-8-831] which may be explained by differences in the ethnicity of samples, methodological discrepancies regarding the clinical signs used to define MGD or its severity and assessment of clinical symptoms, and differences in age distribution across the studies. However, MGD is often underdiagnosed and overlooked. The International Workshop on Meibomian Gland Dysfunction in 2011 defined MGD as a chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/quantitative changes in glandular secretion. This may result in alteration of the tear film, symptoms of eye irritation, clinically apparent inflammation, and ocular surface disease.[@b6-opth-8-831]

The goal of treatment for MGD is to improve the flow of meibomian gland secretions, thus leading to normal tear film stability.[@b7-opth-8-831] Overall, treatment varies widely, and includes warm compresses, lid massage, lid hygiene, artificial lubricants, eye (lipid) ointments, topical antibiotic and anti-inflammatory agents, and tetracycline derivatives, although in many cases treatment may be frustrating for both patients and ophthalmologists.[@b8-opth-8-831],[@b9-opth-8-831] Oral supplementation with omega-3 essential fatty acids has been proposed as a possible therapeutic option for patients with MGD. Given that meibum in MGD is often abnormal, it is possible that the lipid composition of meibum can be influenced by changes in dietary lipid intake. Clinical studies have demonstrated an association between the use of oral omega-3 supplements and improvement in symptoms of dry eye, tear stability, and tear secretion in different scenarios, including in patients with MGD.[@b10-opth-8-831]--[@b19-opth-8-831]

On the other hand, dry eye has been reported to negatively impact both general quality of life and vision-related daily life.[@b20-opth-8-831],[@b21-opth-8-831] In a previous randomized double-masked trial of 3 months' duration, dietary supplementation based on a combination of omega-3 essential fatty acids and antioxidants (1.5 g/day) resulted in significant improvement in the mean Ocular Surface Disease Index, tear breakup time, Schirmer I test, lid margin inflammation, and meibomian gland expression (secretion) by means of a slit-lamp examination, as compared with baseline.[@b19-opth-8-831] In this study, the 36-Item Short Form Health Survey (SF-36)[@b22-opth-8-831] was used as a generic instrument for assessment of health-related quality of life (HRQoL).

The objective of this study was to assess the impact of oral supplementation with a combined formulation of omega-3 essential fatty acids and antioxidants on HRQoL in patients with MGD when compared with placebo. As far as we are aware, extension of the potential benefits of oral omega-3 nutritional supplements beyond ocular symptoms, especially in patients with MGD, has not been previously evaluated.

Materials and methods
=====================

Patients of either sex, aged 18--85 years and diagnosed with MGD according to the criteria identified at a 2011 International Workshop on Meibomian Gland Dysfunction[@b23-opth-8-831] were invited to participate in a randomized, double-masked study during a routine ophthalmologic appointment at the University Hospital Jiménez Díaz Foundation, in Madrid, Spain. Patients were recruited between March 2012 and December 2012 during ophthalmologic appointments at the study center. Patients with blepharitis but without an MGD diagnosis, and those with ocular disorders and using eye drops other than artificial tears, atopic or allergic disorders, systemic diseases (eg, Sjögren's syndrome) and general treatments (eg, ocular hypertension), wearers of contact lenses, and pregnant women were excluded from the study. The study protocol was approved by the ethics committee of the hospital: Comité Ético de la Fundación Jiménez Díaz (CEIC-FJD) and the institutional review board of the University Hospital Jiménez Díaz Foundation, and written informed consent was obtained from all participants. The tenets of the Declaration of Helsinki for the protection of human subjects in medical research were strictly observed.

The primary objective of the study was to assess whether an oral nutraceutical formulation taken over a 3-month period could improve HRQoL as compared with placebo. Patients were visited at baseline (visit 0) and at the end of the study (3 months later). At the baseline visit, the patient's eligibility was assessed, the informed consent form was signed, and the participant was randomly assigned to group A or group B. Group A patients (controls) received an oral placebo supplement, ie, 500 mg capsules containing sunflower oil with no other components or excipients apart from gelatin (bovine) and titanium oxide colorants, iron oxide, and hydroxides. Participants in group B received the oral study supplement (Brudysec^®^ 1.5 g; Brudy Laboratories, Barcelona, Spain). The composition of the supplement formulation is shown in [Table 1](#t1-opth-8-831){ref-type="table"}. Patients were instructed to take three capsules of the study medication (Brudysec 1.5 g or placebo) daily.

At baseline and at the 3-month follow-up visit, patients completed the SF-36 questionnaire using a Spanish validated version.[@b24-opth-8-831],[@b25-opth-8-831] The SF-36 is a multipurpose, short-form health survey with 36 questions. It yields an eight-scale profile of functional health, including physical functioning, role limitation because of physical disability, bodily pain, general health, vitality, social functioning, emotional limitation because of emotional disability, and mental health. These eight scales can be aggregated into two summary measures known as the Physical (PCS) and Mental (MCS) Component Summary scores. The scores range between 0 and 100, with higher scores representing better self-reported health. For the purpose of the study, the summary scores were used to minimize problems with multiple comparisons.

Safety was evaluated by ophthalmological examination and any adverse events that occurred during the study period. Patients could withdraw from the study of their own free will at any time, and could be withdrawn in the event of adverse events identified by ophthalmological criteria or if they developed concomitant illness potentially requiring specific nutritional treatment.

Statistical analysis
--------------------

The data are expressed as the mean ± standard deviation, with differences in PCS and MCS scores between baseline and after 3 months expressed as the mean ± standard deviation and 95% confidence intervals (CIs). Data from patients in groups A and B were compared using the Student's *t*-test for paired independent samples. Statistical significance was set at *P*\<0.05. All statistical analyses were done using Statistical Package for the Social Sciences version 11.0 software (SPSS Inc., Chicago, IL, USA).

Results
=======

Sixty-four patients met our inclusion criteria and were recruited into the study. Thirty-one patients were assigned to group A (controls) and 33 to group B. However, three patients from group B (9.1%) withdrew from the study, two because of fish-tasting regurgitation (n=2) and one for reasons not related to the study formulation, leaving 61 patients who completed the trial, comprising 31 (50.8%) in group A and 30 (49.2%) in group B. There were no significant differences between patients assigned to group A and those assigned to group B with regard to sex distribution (women comprising 71% versus 72.8%, respectively), mean age (54 years versus 58 years) or signs and symptoms of MGD, as Oleñik et al presented in a previous study.[@b19-opth-8-831] Both investigators and patients were blinded to treatment assignment throughout the study.

As shown in [Table 2](#t2-opth-8-831){ref-type="table"}, there were no significant differences in PCS and MCS scores at baseline between the two study groups, but after 3 months of treatment, significantly higher mean PCS and MSC scores were observed in patients treated with the active omega-3 dietary supplement as compared with controls (mean PCS score 53.33±5.57 versus 47.46±7.31, *P*=0.008; mean MCS score 54.60±5.64 versus 47.80±8.45, *P*=0.0005). Moreover, compared with baseline, scores at 3 months were significantly improved for patients in group B (mean PCS score 7.14±5.81, 95% CI 4.97--9.31, *P*=0.000; mean MCS score 5.96±7.64, 95% CI 3.10--8.81, *P*=0.0002), but not for patients in group A ([Table 3](#t3-opth-8-831){ref-type="table"}). No serious adverse events occurred during the study.

Discussion
==========

This randomized, double-masked, 3-month clinical study demonstrates the positive impact of daily oral supplementation with a nutraceutical formulation (Brudysec 1.5 g) containing omega-3 fatty acids, vitamins, and essential trace elements on HRQoL in patients with MGD. Differences when compared with patients assigned to a placebo group were statistically significant for both the physical and mental components of the SF-36 weighed against baseline. In the present study, we used a generic HRQoL instrument instead of generic visual function or specific dry eye questionnaires.[@b26-opth-8-831] A number of studies have shown the detrimental effect of dry eye syndrome on vision-related quality of life.[@b27-opth-8-831]--[@b29-opth-8-831] On the other hand, impairment of vision-related quality of life has shown a significant correlation with the severity of dry eye syndrome.[@b30-opth-8-831] Blepharitis and MGD also deserve attention because they present substantial quality of life issues for patients, eg, the need to apply warm compresses and cleanse the eye with diluted baby shampoo on a daily basis. However, HRQoL has not previously been examined in a homogeneous group of patients with MGD.

A number of mechanisms have been proposed via which supplementation with omega-3 essential fatty acids can alleviate MGD.[@b12-opth-8-831] It has been hypothesized that overwhelming the fatty acid metabolic pathway with omega-3 fatty acid molecules results in competitive inhibition of omega-6 fatty acid metabolism (omega-6 fatty acids produce molecules promoting inflammation), thus leading to decreased inflammation in the eyelid margin and in the meibomian gland region. Further, the present study was done in Spain, where the diet is based on sunflower oil and olive oil, so the intake of 1.5 g sunflower oil (placebo), which is high in omega-6 fatty acids, should be considered residual in inflammation study. Given that blepharitis, MGD, and dry eye are thought to be inflammatory diseases,[@b23-opth-8-831],[@b31-opth-8-831] a reduction in the systemic inflammatory state may alleviate blepharitis, MGD, and dry eye-associated discomfort. Another hypothesis concerns the composition of tear film. It has been suggested that unstable tear film results from abnormal meibomian gland secretions and can result in evaporative dry eye.

Supplementing the diet with high amounts of omega-3 fatty acids is likely to change the fatty acid composition and therefore the properties of meibomian gland secretions. This change may be beneficial in tear stabilization and may prevent inflammation from blocking the meibomian gland ducts and stagnation of meibum. Decreased inflammation of the lid margins and recovery of homeostasis of the ocular surface, along with significant improvement in HRQoL, was observed as a result of improved tear film stability in patients with MGD assigned to the omega-3 dietary supplement. Thus, omega-3 fatty acids inhibit proinflammatory factors. On the other hand, dietary antioxidants can decrease the oxidizing stress (potentially improving quality of life), but in this case the antioxidant does not decrease the MGD inflammation process. Therefore, 3 months of treatment with the supplement, prescribed as three capsules a day, was associated with statistically significant differences for all comparisons (PCS and MCS scores) between baseline and the end of treatment. Moreover, the mean differences in scores at 3 months versus baseline were significantly greater in the group assigned to active omega-3 supplementation as compared with controls. However, because omega-3 cannot be synthesized in the body, dietary supplementation with omega-3 should be encouraged in clinical practice to ameliorate symptoms of dry eye related to MGD[@b19-opth-8-831] and to improve HRQoL.

A limitation of this study was the lack of control over patients' dietary intake. However, the randomized and double-masked design is a strength of the study, along with the fact that the data obtained are relevant to daily clinical practice.

Conclusion
==========

This study was carried out in a homogeneous group of patients with MGD and shows that dietary supplementation with a combination of omega-3 essential fatty acids and antioxidants is an effective adjunctive treatment for improvement of quality of life when a generic HRQoL instrument (SF-36) is used. Further studies of longer duration and including larger patient populations are needed to assess whether the benefits of omega-3 supplementation on quality of life can be maintained in the long-term.
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###### 

Composition of Brudysec^®^ 1.5 g

  Composition                               Per capsule    Percent recommended daily amount   Per three capsules   Percent recommended daily amount
  ----------------------------------------- -------------- ---------------------------------- -------------------- ----------------------------------
  Concentrated oil in omega-3 fatty acids   500 mg         --                                 1,500 mg             --
   TG-DHA 70%                               350 mg         --                                 1,050 mg             --
   EPA 8.5%                                 42.5 mg        --                                 127.5 mg             --
   DPA 6%                                   30 mg          --                                 90 mg                --
  Vitamins                                                                                                         
   Vitamin A (retinol)                      133.33 μg RE   16.66                              400 μg RE            50
   Vitamin C (ascorbic acid)                26.7 mg        33                                 80 mg                100
   Vitamin E (d-α-tocopherol)               4 mg TE        33                                 12 mg α-TE           100
  Essential trace elements                                                                                         
   Zinc                                     1.6 mg         16.6                               5 mg                 50
   Copper                                   0.16 mg        16.6                               0.5 mg               50
   Magnesium                                0.33 mg        16.6                               1 mg                 50
   Selenium                                 9.17 μg        16.6                               27.5 μg              50
  Other components                                                                                                 
   Tyrosine                                 10.8 mg        --                                 32.5 mg              --
   Cysteine                                 5.83 mg        --                                 17.5 mg              --
   Glutathione                              2 mg           --                                 6 mg                 --

**Note:** Brudysec^®^ 1.5 g, Brudy Laboratories, Barcelona, Spain.

**Abbreviations:** TG-DHA, triglyceride-bound docosahexaenoic acid; EPA, eicosapentaenoic acid; DPA, docosapentaenoic acid; RE, retinol equivalents; TE, tocopherol equivalents.

###### 

Changes in health-related quality of life (SF-36) at the end of the study (3 months) as compared with baseline in the two study groups

  Study group                                          Mean PCS (SD) score   Mean MCS (SD) score                   
  ---------------------------------------------------- --------------------- --------------------- --------------- --------------
  A, n=31[\*](#tfn3-opth-8-831){ref-type="table-fn"}   49.16 (8.76)          47.46 (7.31)          49.20 (10.65)   47.80 (8.45)
  B, n=30[†](#tfn4-opth-8-831){ref-type="table-fn"}    46.19 (8.25)          53.33 (5.57)          48.64 (9.20)    54.60 (5.64)
  *P*-value                                            0.178                 0.008                 0.827           0.0005

**Notes:**

Group A patients treated with placebo (control).

Group B patients treated using dietary supplementation with a combination of omega-3 polyunsaturated fatty acids and antioxidants (Brudysec^®^ 1.5 g; Brudy Laboratories, Barcelona, Spain).

**Abbreviations:** PCS, Physical Component Summary; MCS, Mental Component Summary; SF-36, 36-Item Short Form Health Survey; SD, standard deviation.

###### 

Mean differences in health-related quality of life (SF-36) in the two study groups at the end of the study (3 months) as compared with baseline

  Study group                                          PCS score (3 months versus baseline)   MCS score (3 months versus baseline)                                          
  ---------------------------------------------------- -------------------------------------- -------------------------------------- ------- -------------- --------------- --------
  A, n=31[\*](#tfn6-opth-8-831){ref-type="table-fn"}   −1.70 (4.69)                           −3.42 to 0.02                          0.052   −1.41 (5.46)   −3.41 to 0.60   0.161
  B, n=30[†](#tfn7-opth-8-831){ref-type="table-fn"}    7.14 (5.81)                            4.97--9.31                             0.000   5.96 (7.64)    3.10--8.81      0.0002

**Notes:**

Group A patients treated with placebo (controls).

Group B patients treated with dietary supplementation with a combination of omega-3 polyunsaturated fatty acids and antioxidants (Brudysec^®^ 1.5 g, Brudy Laboratories, Barcelona, Spain).

**Abbreviations:** PCS, Physical Component Summary; MCS, Mental Component Summary; CI, confidence interval; SF-36, 36-Item Short Form Health Survey; SD, standard deviation.
